A new verification link is sent. Check email. Resend confirmation email
SAPHNELO 300mg/2ml (International English)
$3,799.00
| Quantity | Discount (%) | Price |
|---|---|---|
| 1 - 5 | — | $3,799.00 |
| 6 - 10 | 1.32 % | $3,749.00 |
| 11 - 20 | 2.63 % | $3,699.00 |
| 21+ | 3.95 % | $3,649.00 |
Anifrolumab-fnia is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody. It selectively binds to subunit 1 of the type I interferon (IFN) receptor (IFNAR1). By binding to IFNAR1, Saphnelo inhibits the signaling pathways mediated by type I interferons, effectively blocking their biological activity. In SLE, there is often an overexpression of type I IFN-inducible genes, contributing to the disease’s immune system dysregulation. By blocking the Type I IFN receptor, Saphnelo aims to reduce this overactivity and improve lupus symptoms.



